Leadership
Our team of passionate biopharmaceutical leaders combines deep expertise in drug development and commercialization
Meet our leadership teamLatest news
View more news >Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
Rare perspective
Insights and information on our approach to collaborating with rare disease communities, supporting our teammates at Ultragenyx, and developing new therapies for rare disease
Read our blog >